Roivant Sciences Ltd
General ticker "ROIV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.0B
Roivant Sciences Ltd follows the US Stock Market performance with the rate: 51.0%.
Estimated limits based on current volatility of 1.6%: low 11.58$, high 11.95$
Factors to consider:
- Current price 49.7% above estimated high
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-03-31 to 2025-03-30
- 2023-03-31 to 2024-03-30 estimated range: [4.64$, 8.61$]
- 2024-03-30 to 2025-03-30 estimated range: [4.19$, 8.00$]
Short-term ROIV quotes
Long-term ROIV plot with estimates
Financial data
| YTD | 2022-03-31 | 2023-03-31 |
|---|---|---|
| Operating Revenue | $55.29MM | $61.28MM |
| Operating Expenses | $1,406.93MM | $1,236.60MM |
| Operating Income | $-1,351.64MM | $-1,175.32MM |
| Non-Operating Income | $427.89MM | $-49.52MM |
| Interest Expense | $7.04MM | $27.97MM |
| R&D Expense | $483.04MM | $525.22MM |
| Income(Loss) | $-923.75MM | $-1,224.83MM |
| Taxes | $0.37MM | $5.19MM |
| Other Income(Loss) | $0.00MM | $114.56MM |
| Profit(Loss) | $-924.12MM | $-1,115.46MM |
| Stockholders Equity | $1,656.94MM | $1,157.77MM |
| Inventory | $0.00MM | $2.76MM |
| Assets | $2,585.13MM | $2,389.60MM |
| Operating Cash Flow | $-677.73MM | $-843.39MM |
| Capital expenditure | $17.44MM | $12.69MM |
| Investing Cash Flow | $303.30MM | $-44.27MM |
| Financing Cash Flow | $306.79MM | $499.46MM |
| Earnings Per Share* | $-1.26 | $-1.42 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.